Research Article| Volume 33, SUPPLEMENT 4, S44-S49, May 1997

Antimicrobial therapy in cancer patients: Studies from the EORTC international antimicrobial therapy cooperative group

  • S.H. Zinner
    Department of Medicine, Brown University, Division of Infectious Diseases, Rhode Island Hospital and Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, Rhode Island 02908, U.S.A.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.
      Patients with cancer are subject to infections as a result of several factors, notably obstruction or constriction of airways or ducts, erosion of tumour involving the protective integument or mucosa, alteration of host defenses secondary to infiltration of bone marrow, reduced or altered immunoglobulin or cytokine production, or as a result of chemotherapy. Specific infecting organisms may be predicted based on the specific defect in host defenses. For example, patients with myeloma or lymphocytic leukaemia may develop infections with encapsulated bacteria as a result of decreased B-lymphocyte numbers or function, and those with lymphomas may incur a variety of intracellular bacterial, fungal, and viral infections as a result of decreased T-lymphocyte function. Neutropenia is the most frequently encountered host cell defect in patients with cancer and predicts the development of bacteraemia caused by Gram-positive and Gram-negative bacteria. Recent changes in microbial ecology and antimicrobial resistance profiles have highlighted the need for continued reevaluation of antimicrobial therapy in these patients. Several new antibiotics with enhanced activity against organisms frequently isolated from patients with cancer have been introduced and studied recently. The International Antimicrobial Therapy Cooperative Group of the EORTC has studied meropenem alone, piperacillin/tazobactam, and ceftriaxone, each with single daily dose amikacin; these regimens compare favourably with ceftazidime plus amikacin for empirical treatment of fever in neutropenic patients. Preventive measures are important, if understudied, and the optimal antibiotic approach to prophylaxis remains unclear. Adjunctive measures including prophylactic and therapeutic colony-stimulating factors play an important role.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • The EORTC International Antimicrobial Therapy Project Group
        Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer.
        J Infect Dis. 1978; 137: 14-29
        • Calandra T
        • Klastersky J
        • Gaya H
        • Glauser MP
        • Meunier F
        • Zinner SH
        • EORTC International Antimicrobial Therapy Cooperative Group
        Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.
        N Engl J Med. 1987; 317: 1692-1698
        • EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada—Clinical Trials Group
        Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients.
        J Infect Dis. 1991; 35: 873-878
        • Zinner SH
        New and unusual infections in neutropenic patients.
        in: Klastersky J Infectious Complications of Cancer. Kluwer, London1995: 173-184
        • Zinner SH
        Treatment and prevention of infection in immunocompromised hosts.
        in: Gorbach SL Bartlett JG Blacklow NR Infectious Diseases. W.B. Saunders, Boston1992: 1057-1064
        • Glauser MP
        • Zinner SH
        Mechanisms of the acquisition of bacterial infections in cancer patients.
        in: Klastersky J Infection in Cancer Patients. Raven Press, Philadelphia1982: 13-24
        • Edmond MB
        • Ober JF
        • Weinbaum DL
        • et al.
        Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.
        Clin Infect Dis. 1995; 20: 1126-1133
        • The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer
        Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia.
        Ann Intern Med. 1993; 119: 584-593
        • Cometta A
        • Zinner S
        • deBock R
        • et al.
        Piperacillin—tazobactam versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer.
        Antimicrob Agents Chemother. 1995; 39: 445-452
        • Cometta A
        • Calandra T
        • Gaya H
        • et al.
        Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer.
        Antimicrob Agents Chemother. 1996; 40: 1108-1115
        • De Pauw BE
        • Deresinski SC
        • Feld R
        • Lane-Allman EF
        • Donnelly JP
        Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial.
        Ann Intern Med. 1994; 120: 834-844
        • Freifeld AG
        • Walsh T
        • Marshall D
        • et al.
        Monotherapy for fever and neutropenia in cancer patient: a randomized comparison of ceftazidime versus imipenem.
        J Clin Oncol. 1995; 13: 165-176
        • Meropenem Study Group of Leuven, London and Nijmegen
        Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients.
        J Antimicrob Chemother. 1995; 36: 185-200
        • Talcott JA
        • Siegel RD
        • Finberg R
        • Goldman L
        Risk assessment in cancer patients with fever and neutropenia: a prospective, two center validation of a prediction rule.
        J Clin Oncol. 1992; 10: 316-322
        • Whitley RJ
        • Gnann Jr, JW
        Acyclovir: a decade later.
        N Engl J Med. 1992; 327: 782-789
        • Schmidt GM
        • Horak DA
        • Niland JC
        • et al.
        A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants.
        N Engl J Med. 1991; 324: 1005-1011
        • Talcott JA
        • Whalen JC
        • Rieker PP
        • Finberg R
        Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule.
        J Clin Oncol. 1994; 12: 107-114
        • Rubenstein E
        • Rolston K
        Outpatient management of febrile episodes in neutropenic cancer patients.
        Support Care Cancer. 1994; 2: 369-373
        • American Society of Clinical Oncology
        Recommendations for the use of hematopoietic colony stimlating factors: evidence based, clinical practice guidelines.
        J Clin Oncol. 1994; 12 (Anon.): 2471-2508
        • Dibenedetto SP
        • Ragusa R
        • Ippolito AM
        • et al.
        Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymphoblastic leukaemia: a randomized clinical trial.
        Eur J Haematol. 1995; 55: 93-96
        • Stone RM
        • Berg DT
        • George SL
        • et al.
        Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
        N Engl J Med. 1995; 332: 1671-1677
        • Hester JP
        • Dignani MC
        • Anaissie EJ
        • Kantarjian HM
        • O'Brien S
        • Freireich EJ
        Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection.
        J Clin Apheresis. 1995; 10: 188-193
        • Zinner SH
        Prophylactic uses of fluoroquinolone antibiotics.
        Infect Dis in Clin Practice. 1994; 3: S203-S210
        • EORTC International Antimicrobial Therapy Group
        Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients.
        J Infect Dis. 1984; 150: 372-379
        • International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer
        Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin.
        JAMA. 1994; 272 (Writing Committee: Zinner S, Calandra T, Meunier F, Gaya H, Viscoli C, Klastersky J, Glauser MP, Langenaeken J, and Paesmans M): 1183-1189
        • Cruciani M
        • Rampazzo R
        • Malena M
        • et al.
        Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis.
        Clin Infect Dis. 1996; 23: 795-805